New pill targets rare genetic flaw in Hard-to-Treat cancers
NCT ID NCT04683250
First seen Mar 11, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tests an experimental drug (TAS0953/HM06) in adults with advanced solid tumors that have a specific RET gene abnormality. The first part finds the safest dose; the second part measures how well the drug shrinks tumors. About 244 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RET-ALTERED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chao Family Comprehensive Cancer Center
TERMINATEDOrange, California, 92868-3298, United States
-
Henry Ford Hospital
TERMINATEDDetroit, Michigan, 48202, United States
-
Kanagawa Cancer Center
RECRUITINGKanagawa, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kansai Medical University Hospital
RECRUITINGHirakata-shi, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kurashiki Central Hospital
RECRUITINGOkayama, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
TERMINATEDNew York, New York, 10016, United States
-
Massachusetts General Hospital
TERMINATEDBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
TERMINATEDNew York, New York, 10065, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, Chiba, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Hospital Organization Kyushu Cancer Center
RECRUITINGFukuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Okayama University Hospital
RECRUITINGOkayama, Okayama-ken, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Osaka International Cancer Institute
RECRUITINGOsaka, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest - Cancer & Hematology Centers of Western Michigan
TERMINATEDGrand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shizuoka Cancer Center
RECRUITINGShizuoka, Shizuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford Cancer Center
TERMINATEDStanford, California, 94305-5826, United States
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sarah Cannon Research Institute/Tennessee Oncology
TERMINATEDNashville, Tennessee, 37203, United States
-
The University of Texas M. D. Anderson Cancer Center
TERMINATEDHouston, Texas, 77030-4009, United States
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.